Such a reduction in functional performance could negatively influence central nervous system signaling pathways, specifically those involving dynorphin and dopamine, which could potentially exacerbate the pathophysiology of bipolar disorder in affected individuals. This evidence concerns the gene PDYN and bipolar disorder.